Among Japanese patients , median overall survival was not estimable ( @ % confidence interval , @ months-not estimable ) with axitinib/gemcitabine ( n = @ ) and @ months ( @ % confidence interval , @-@ @ ) with placebo/gemcitabine ( n = @ ) ( hazard ratio @ -LSB- @ % confidence interval , @-@ @ -RSB- ) .